newsfilter
← Latest News
GlobeNewswire·

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

  • Abivax SA requested a temporary trading halt for its ordinary shares on Euronext Paris starting at 9:00 a.m. CEST on July 1, 2026.
  • The halt is intended to allow for the confirmation of investor allocations & the announcement of pricing for the company's public offering of American Depositary Shares in the United States.
  • Trading on Euronext Paris is expected to resume on July 1, 2026, at approximately 3:30 p.m. CEST.
  • The suspension remains in effect until a new communication is released by the company.
  • Abivax is a clinical-stage biotechnology company developing therapeutics to stabilize immune responses in patients with chronic inflammatory diseases.
  • The company's lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for moderately to severely active ulcerative colitis.